Are you ready for the new realities?
We have entered an era of profound transformation in life sciences. The landscape is changing rapidly. Managing through — and thriving in — this era of continuous change requires regular, robust and well-organized risk assessment and prioritization.
EY projects that by 2025 many life sciences companies will have transitioned toward more integrated commercial business models, offering products and services designed to improve outcomes and addressing the specific needs of a broad array of customer groups.
This will involve developing more outcome-based contracting models and instilling a patient-centric corporate culture. Mass customization, enabled by continuous technological advancements and a host of new health care players, will characterize the market. Regulatory compliance will be more complex, yet still critical to consumer trust and competitiveness.